Rani Therapeutics Holdings(RANI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

RANI Rani Therapeutics Holdings

Trading 04-15 14:08:39 EDT

0.9575

+0.1202

+14.36%

High0.9575	Low0.8451	Vol584.34K
Open0.8600	D1 Closing0.8373	Amplitude13.42%
Mkt Cap118.44M	Tradable Cap64.05M	Total Shares123.69M
T/O529.95K	T/O Rate0.87%	Tradable Shares66.89M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"RANI","market":"US","secType":"STK","nameCN":"Rani Therapeutics Holdings","latestPrice":0.9575,"timestamp":1776276494714,"preClose":0.8373,"halted":0,"volume":584337,"delay":0,"changeRate":0.1435566702496118,"floatShares":66891000,"shares":123692286,"eps":-0.45,"marketStatus":"Trading","change":0.1202,"latestTime":"04-15 14:08:39 EDT","open":0.86,"high":0.9575,"low":0.8451,"amount":529947.0873411,"amplitude":0.134241,"askPrice":0.9576,"askSize":110,"bidPrice":0.9502,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-0.45,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1776283200000},"marketStatusCode":2,"adr":0,"listingDate":1627617600000,"exchange":"NASDAQ","adjPreClose":0.8373,"preHourTrading":{"tag":"盘前","latestPrice":0.85,"preClose":0.8373,"latestTime":"09:10 EDT","volume":5585,"amount":4762.067563500001,"timestamp":1776258634944,"change":0.0127,"changeRate":0.015168,"amplitude":0.032247},"postHourTrading":{"tag":"盘后","latestPrice":0.8487,"preClose":0.8373,"latestTime":"19:45 EDT","volume":16551,"amount":13840.80417,"timestamp":1776210353919,"change":0.0114,"changeRate":0.013615,"amplitude":0.034635},"volumeRatio":0.721961,"impliedVol":1.7277,"impliedVolPercentile":0.716},"requestUrl":"/m/hq/s/RANI/tweets","defaultTab":"tweets","newsList":[{"id":"2626864251","title":"Rani Therapeutics names Sara Kenkare-Mitra strategic advisor on platform, clinical strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2626864251","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626864251?lang=en_us&edition=fundamental","pubTime":"2026-04-09 19:03","pubTimestamp":1775732635,"startTime":"0","endTime":"0","summary":"Rani Therapeutics appointed Sara Kenkare-Mitra as strategic advisor to shape platform and clinical strategy.Her remit includes therapeutic area focus, product selection, development prioritization, regulatory alignment, market positioning.Kenkare-Mitra most recently served as president and head of R&D at Alector.She previously spent more than 20 years at Genentech, working on development and approvals of multiple therapies and advancing antibody-drug conjugate platform.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nNDL8dLyzf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","IE00BKPKM429.USD","BK4539","IE00B3QW5Z07.USD","SG9999014005.SGD","BK4007","IE00BN0W2W23.USD","LU2210149790.SGD","IE00B64PRP62.GBP","BK4139","LU0314104364.USD","RANI","SG9999014039.USD","BK4112","SG9999014021.USD","SG9999014013.SGD","BK4585","IE00BGHQF748.EUR","IE00BN0W2T93.GBP","LU2095319765.USD","ALEC","LU2210150020.SGD","NDAQ","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624751179","title":"Analysts Conflicted on These Healthcare Names: Rani Therapeutics Holdings (RANI) and Apellis Pharmaceuticals (APLS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2624751179","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624751179?lang=en_us&edition=fundamental","pubTime":"2026-04-01 22:00","pubTimestamp":1775052020,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Rani Therapeutics Holdings (RANI) and Apellis Pharmaceuticals (AP...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-rani-therapeutics-holdings-rani-and-apellis-pharmaceuticals-apls-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-rani-therapeutics-holdings-rani-and-apellis-pharmaceuticals-apls-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","BK4588","BK4585","LABU","RANI","LU1093756325.SGD","BK4581","HCSG","LU0128526141.USD","BK4007","BK4139","XLV","LU0029874061.USD","BK4539","APLS","LU1093756168.USD","BK4137","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622922809","title":"Rani Therapeutics files initial beneficial ownership statement; Chief Technical Officer Alireza Javadi reports 10,075 Class A shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2622922809","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622922809?lang=en_us&edition=fundamental","pubTime":"2026-03-28 07:47","pubTimestamp":1774655267,"startTime":"0","endTime":"0","summary":"Rani Therapeutics files initial beneficial ownership statement; Chief Technical Officer Alireza Javadi reports 10,075 Class A shares. Rani Therapeutics Chief Technical Officer Alireza Javadi reported direct ownership of 10,075 shares of Class A common stock in an initial Form 3 filing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rani Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 27, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDL4D0JQy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4539","RANI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622894336","title":"Rani Therapeutics Holdings Inc reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2622894336","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622894336?lang=en_us&edition=fundamental","pubTime":"2026-03-27 05:38","pubTimestamp":1774561121,"startTime":"0","endTime":"0","summary":"Rani Therapeutics Holdings Inc reports results for the quarter ended September 30 - Earnings SummaryRani Therapeutics Holdings Inc RANI.OQ reported a quarterly adjusted loss of 12 cents per share for ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nL8N40E2KE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RANI","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622349899","title":"Rani Therapeutics' net loss narrows in Q4 as costs fall","url":"https://stock-news.laohu8.com/highlight/detail?id=2622349899","media":"Reuters","labels":["corporation","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622349899?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:26","pubTimestamp":1774556817,"startTime":"0","endTime":"0","summary":"Rani Therapeutics' net loss narrows in Q4 as costs fallOverviewU.S. biotherapeutics developer's Q4 net loss narrowed as operating expenses declinedCompany completed $60.3 mln private placement and ent","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nL1N40E154:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4007","RANI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622896296","title":"Rani Therapeutics FY2025 net loss narrows 27.6% to $41 million; revenue rises 58.9% to $1.6 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622896296","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622896296?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:11","pubTimestamp":1774555868,"startTime":"0","endTime":"0","summary":"Rani published a press release reporting fourth-quarter and full-year 2025 financial results and a corporate update.Contract revenue was USD 1.5 million in Q4 and USD 1.6 million in FY 2025, up 42.12% and 58.85%, respectively, driven mainly by revenue attributed to a license and collaboration agreement.Net loss was USD 9.1 million in Q4 and USD 41.0 million in FY 2025, narrowing 42.27% and 27.55%, respectively.R&D expense was USD 4.9 million in Q4 and USD 20.2 million in FY 2025, down 27.93% and 24.3%, respectively, primarily due to lower compensation costs and other cost-containment measures including pausing or terminating certain R&D programs.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rani Therapeutics Holdings Inc. published t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL3S7Tvm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4007","RANI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622289660","title":"Rani Therapeutics Q4 Operating Expenses USD 9.995 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622289660","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622289660?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:05","pubTimestamp":1774555501,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nPLX5A12F0:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4007","RANI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622891613","title":"Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2622891613","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622891613?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:05","pubTimestamp":1774555500,"startTime":"0","endTime":"0","summary":"- Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics and completed $60.3 million oversubscribed private placement led by Samsara BioCapita","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/26/3263414/0/en/Rani-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","LENZ","BK4539","RANI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622898713","title":"Rani Therapeutics Holdings options imply 17.3% move in share price post-earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2622898713","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622898713?lang=en_us&edition=fundamental","pubTime":"2026-03-27 02:20","pubTimestamp":1774549216,"startTime":"0","endTime":"0","summary":"Pre-earnings options volume in Rani Therapeutics (RANI) Holdings is 1.1x normal with calls leading puts 24:1. Implied volatility suggests the marke...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rani-therapeutics-holdings-options-imply-17-3-move-in-share-price-post-earnings-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rani-therapeutics-holdings-options-imply-17-3-move-in-share-price-post-earnings-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RANI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622007889","title":"Press Release: Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization","url":"https://stock-news.laohu8.com/highlight/detail?id=2622007889","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622007889?lang=en_us&edition=fundamental","pubTime":"2026-03-26 04:53","pubTimestamp":1774471980,"startTime":"0","endTime":"0","summary":"SAN JOSE, Calif., March 25, 2026  -- Rani Therapeutics Holdings, Inc.  , a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the appointment of Jesper Hiland as Head of Strategy. Mr. Hiland has served as a strategic adviser to the company since 2023 and brings more than 30 years of global pharmaceutical leadership experience, including extensive expertise in obesity and metabolic disease.\"What attracted me to Rani is the strength of its platform and the breadth of opportunity it creates across multiple therapeutic areas,\" said Mr. Hiland. \"The ability to deliver biologics orally has the potential to reshape treatment paradigms, and I believe Rani i","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LENZ","RANI","BK4539","BK4232","R","BK4139","BK4022"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622013980","title":"Rani Therapeutics Holdings Inc  expected to post a loss of 7 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2622013980","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622013980?lang=en_us&edition=fundamental","pubTime":"2026-03-25 04:26","pubTimestamp":1774383972,"startTime":"0","endTime":"0","summary":"Rani Therapeutics Holdings Inc  expected to post a loss of7cents a share - Earnings Preview Rani Therapeutics Holdings Inc RANI.OQ RANI.O is expected to  show a rise in quarterly revenue when it repor","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nL8N40C2P8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4007","RANI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621751021","title":"Rani Therapeutics Holdings Inc  expected to post a loss of 7 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2621751021","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621751021?lang=en_us&edition=fundamental","pubTime":"2026-03-21 04:39","pubTimestamp":1774039145,"startTime":"0","endTime":"0","summary":"Rani Therapeutics Holdings Inc  expected to post a loss of7cents a share - Earnings Preview Rani Therapeutics Holdings Inc RANI.OQ RANI.O is expected to  show a rise in quarterly revenue when it repor","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nL8N4082BF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RANI","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620761952","title":"Rani Therapeutics Holdings Inc. to report Q4 and full-year 2025 financial results","url":"https://stock-news.laohu8.com/highlight/detail?id=2620761952","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620761952?lang=en_us&edition=fundamental","pubTime":"2026-03-20 04:05","pubTimestamp":1773950712,"startTime":"0","endTime":"0","summary":"Rani Therapeutics plans to release financial results for the fourth quarter and full year ended December 31, 2025 on March 26, 2026 after market close.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL7sStWK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","LU2210149790.SGD","RANI","BK4588","BK4007","BK4585","BK4539","SG9999014021.USD","SG9999014039.USD","NDAQ","IE00BN0W2T93.GBP","SG9999014005.SGD","SG9999014013.SGD","IE00BN0W2W23.USD","IE00BGHQF748.EUR","BK4112","LU2095319765.USD","LU2210150020.SGD","LU0314104364.USD","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608072109","title":"Insider Buyers At Rani Therapeutics Holdings Sitting On US$1.3m Profit","url":"https://stock-news.laohu8.com/highlight/detail?id=2608072109","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608072109?lang=en_us&edition=fundamental","pubTime":"2026-01-31 21:21","pubTimestamp":1769865693,"startTime":"0","endTime":"0","summary":"Insiders who purchased Rani Therapeutics Holdings, Inc. ( NASDAQ:RANI ) shares in the past 12 months are unlikely to be...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rani/rani-therapeutics-holdings/news/insider-buyers-at-rani-therapeutics-holdings-sitting-on-us13","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rani/rani-therapeutics-holdings/news/insider-buyers-at-rani-therapeutics-holdings-sitting-on-us13","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","BK4539","RANI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606671533","title":"Rani Therapeutics Promotes Alireza Javadi to Chief Technical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2606671533","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606671533?lang=en_us&edition=fundamental","pubTime":"2026-01-28 20:01","pubTimestamp":1769601683,"startTime":"0","endTime":"0","summary":"Rani Therapeutics Holdings Inc. has promoted Alireza Javadi, Ph.D., to Chief Technical Officer. Javadi, who previously served as Vice President of Technical Operations, will now also oversee quality assurance in addition to leading R&D, manufacturing, and automation teams. He joined Rani in 2022 after holding operational and engineering roles at Cretex Medical, JunoPacific, G&W Electric Co., and the Wisconsin Institute for Discovery.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rani Therapeutics Holdings Inc. published the original content used to generate this news brief via GlobeNewswire  on January 28, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nNDL55jGhJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","BK4588","BK4112","BK4007","LU2210149790.SGD","SG9999014005.SGD","NDAQ","IE00BKPKM429.USD","BK4539","BK4585","IE00BGHQF748.EUR","LU0314104364.USD","SG9999014039.USD","SG9999014013.SGD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","SG9999014021.USD","LU2210150020.SGD","RANI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606713051","title":"Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.d. to Chief Technical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2606713051","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606713051?lang=en_us&edition=fundamental","pubTime":"2026-01-28 20:00","pubTimestamp":1769601602,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nTUA2MLBH1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RANI","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606736181","title":"Rani Therapeutics Unveils Oral Biologics Platform Targeting Injection-Free Treatments","url":"https://stock-news.laohu8.com/highlight/detail?id=2606736181","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606736181?lang=en_us&edition=fundamental","pubTime":"2026-01-28 00:23","pubTimestamp":1769530997,"startTime":"0","endTime":"0","summary":"Rani Therapeutics Holdings Inc., a clinical-stage biotech company focused on the oral delivery of biologic drugs, has released a new corporate presentation outlining recent developments in its platform technology. The company’s RaniPill device is designed to deliver liquid drug formulations with a capacity of 200 L  and has been tested across 19 different molecules, including antibodies, peptides, and large proteins. According to the presentation, over 7,000 capsules have been evaluated in vitro and in vivo, including a 60-day GLP study with no clinical findings and three completed Phase 1 studies. The RaniPill capsule has been administered to 146 human subjects, and selected pharmacokinetic and pharmacodynamic data suggest comparable bioavailability to subcutaneous injection in preclinical and clinical studies. The internal pipeline focuses on obesity, rare diseases, and immunology, with more than 400 granted patents and pending applications. You can access the full presentation throu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260127:nNDL6PJld8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4539","RANI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2602306120","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Cartesian Therapeutics (RNAC), Rani Therapeutics Holdings (RANI) and Haemonetics (HAE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2602306120","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602306120?lang=en_us&edition=fundamental","pubTime":"2026-01-10 03:51","pubTimestamp":1767988260,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cartesian Therapeutics (RNAC – Research Report), R...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-cartesian-therapeutics-rnac-rani-therapeutics-holdings-rani-and-haemonetics-hae-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-cartesian-therapeutics-rnac-rani-therapeutics-holdings-rani-and-haemonetics-hae-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNAC","HCSG","IE00BLDYK493.USD","LU0128526141.USD","LU0205193047.USD","LU0012050646.USD","BK4585","BK4137","IE00B19Z6F94.USD","RANI","BK4198","BK4581","BK4588","LABU","LU0029874061.USD","HAE","LU0205194284.USD","XBI","BK4007","IE0034390439.USD","BK4139","XLV","IE00B64QTZ34.USD","LU1169590202.USD","BK4539","LU0106261612.USD","LU1169589451.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2602532042","title":"H.C. Wainwright Sticks to Their Buy Rating for Rani Therapeutics Holdings (RANI)","url":"https://stock-news.laohu8.com/highlight/detail?id=2602532042","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602532042?lang=en_us&edition=fundamental","pubTime":"2026-01-09 19:36","pubTimestamp":1767958601,"startTime":"0","endTime":"0","summary":"In a report released today, Brandon Folkes from H.C. Wainwright reiterated a Buy rating on Rani Therapeutics Holdings, with a price target of $11.0...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-their-buy-rating-for-rani-therapeutics-holdings-rani-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-their-buy-rating-for-rani-therapeutics-holdings-rani-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RANI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601536629","title":"Rani Therapeutics Launches Phase 1 Trial of Oral GLP-1/GLP-2 Agonist for Obesity Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2601536629","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601536629?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:01","pubTimestamp":1767873679,"startTime":"0","endTime":"0","summary":"Rani Therapeutics Holdings Inc. has announced the initiation of a Phase 1 clinical trial evaluating RT-114, an orally administered RaniPill capsule containing the GLP-1/GLP-2 dual agonist PG-102, for the treatment of obesity. The study will assess the safety, tolerability, bioavailability, pharmacokinetics, and pharmacodynamics of single and multiple doses of RT-114 compared to subcutaneous injection. Preclinical testing in animal models demonstrated that oral delivery of PG-102 via the RaniPill achieved bioavailability, pharmacokinetics, and weight loss effects comparable to subcutaneous injection. Results from this Phase 1 study have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rani Therapeutics Holdings Inc","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL5xPYzB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","RANI","LU2210149790.SGD","BK4112","IE00B3QW5Z07.USD","BK4007","IE00BGHQF748.EUR","BK4585","SG9999014005.SGD","NDAQ","IE00BKPKM429.USD","SG9999014013.SGD","BK4539","LU0314104364.USD","BK4588","LU2210150020.SGD","SG9999014021.USD","SG9999014039.USD","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ranitherapeutics.com","stockEarnings":[{"period":"1week","weight":0.0241},{"period":"1month","weight":-0.3657},{"period":"3month","weight":-0.4019},{"period":"6month","weight":0.7781},{"period":"1year","weight":-0.3193},{"period":"ytd","weight":-0.3798}],"compareEarnings":[{"period":"1week","weight":0.0535},{"period":"1month","weight":0.0486},{"period":"3month","weight":0.0059},{"period":"6month","weight":0.0512},{"period":"1year","weight":0.2881},{"period":"ytd","weight":0.0184}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.030292},{"month":2,"riseRate":0.8,"avgChangeRate":0.053306},{"month":3,"riseRate":0,"avgChangeRate":-0.236131},{"month":4,"riseRate":0.4,"avgChangeRate":0.177734},{"month":5,"riseRate":0,"avgChangeRate":-0.208482},{"month":6,"riseRate":0.25,"avgChangeRate":-0.118539},{"month":7,"riseRate":0.75,"avgChangeRate":-0.021139},{"month":8,"riseRate":0.4,"avgChangeRate":0.087585},{"month":9,"riseRate":0.2,"avgChangeRate":-0.146008},{"month":10,"riseRate":0.6,"avgChangeRate":0.658105},{"month":11,"riseRate":0.6,"avgChangeRate":0.053129},{"month":12,"riseRate":0.2,"avgChangeRate":-0.107417}],"exchange":"NASDAQ","name":"Rani Therapeutics Holdings","nameEN":"Rani Therapeutics Holdings"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.41.0","shortVersion":"4.41.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Rani Therapeutics Holdings(RANI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Rani Therapeutics Holdings(RANI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Rani Therapeutics Holdings,RANI,Rani Therapeutics Holdings股票,Rani Therapeutics Holdings股票老虎,Rani Therapeutics Holdings股票老虎国际,Rani Therapeutics Holdings行情,Rani Therapeutics Holdings股票行情,Rani Therapeutics Holdings股价,Rani Therapeutics Holdings股市,Rani Therapeutics Holdings股票价格,Rani Therapeutics Holdings股票交易,Rani Therapeutics Holdings股票购买,Rani Therapeutics Holdings股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Rani Therapeutics Holdings(RANI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Rani Therapeutics Holdings(RANI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction